A. Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.
INTRODUCTION
The sarcomere is the contractile unit of striated muscle, including cardiac muscle, and composed of highly organized proteins (6) . Abnormalities in cardiac sarcomeric proteins alter the Ca 2ϩ sensitivity of muscle contraction and lead to cardiomyopathy, eventually causing heart failure (HF) (22) . It has been reported that phosphorylation of myosin light chain (MLC) was involved in the regulation of Ca 2ϩ sensitivity (11, 19) . Two enzymes regulate the phosphorylation status of MLC: MLC kinase (MLCK) and MLC phosphatase (MLCP). The functional role of MLCK in cardiac muscle has been expanding (4, 5, 20) , whereas that of MLCP remains largely unknown.
MLCP is composed of a catalytic ␦-isoform (PP1c␦) subunit and two regulatory subunits, a myosin phosphatase target subunit (MYPT1 or MYPT2) and a small regulatory subunit (sm-M20 or hHS-M 21 ) (10). PP1c␦ binds and requires MYPT to interact with specific substrates such as MLC (7) . Phosphorylation of MYPT by Rho-associated coiled-coil forming kinase (ROCK) signaling inhibits MLCP activity and increases the sensitivity to Ca 2ϩ in the muscle contraction via phosphorylation of MLC (12) . We have previously isolated human heartspecific hHS-M 21 (3) , which increases the Ca 2ϩ sensitivity of cardiac muscle contraction and phosphorylation of MYPT1 (3) . In the present study, we generated transgenic (Tg) mice with cardiac-specific overexpression of hHS-M 21 to evaluate the role of hHS-M 21 in vivo. Here, we report alterations in gene expression and the signaling pathway observed in hearts from hHS-M 21 Tg mice that suffered from cardiomyopathy associated with conduction disturbance.
MATERIALS AND METHODS
Animals. Hexahistidine (His6)-tagged cDNA of hHS-M21 A isoform was cloned into a pBleuscript II SK vector between the mouse ␣-myosin heavy chain (MHC) promoter and bovine growth hormone polyadenylation signal sequences. Transgene fragments containing the promoter and polyadenylation signal sequences were cut using two restriction enzymes (SacI and NaeI) and purified to remove pBleuscript II SK vector completely and injected into the pronuclei of fertilized C57BL/6J mouse oocytes (Fig. 1A) . The resulting pups were screened for the presence of transgene by PCR using a mouse ␣-MHC promoter-specific primer TGM-F (5=-TCTTAGCAAACCTCAG-GCAC-3=) and hHS-M 21-specific primer 602-1000R (5=-TGC-CACGTTTCTTTGACCTC-3=), as shown in Fig. 1A . The transgenecarrying founders were bred to control C57BL/6J mice to check for germline transmission and maintained as Tg lines. Among the obtained Tg lines, lines 29 and 32 (Tg29 and Tg32, respectively, hereafter), with strong expression of the hHS-M 21 transgene, and line 6 (Tg6, hereafter), with weak expression of the hHS-M21 transgene, were used for further experiments in this study. Mice were fed a chow diet and housed in a barrier facility. All care and experimental procedures of animals were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (8th edition, 2011) and subjected to prior approval by the local animal protection authority of Tokyo Medical and Dental University.
Rabbit polyclonal anti-hHS-M 21 antibody. Antisera against the recombinant His6-tagged hHS-M21 protein was made in a rabbit with three 1-mg subcutaneous injections in complete Freund's adjuvant 2 wk apart. Antisera were purified using the PROTEUS Protein G Midi Kit (Generon) and characterized by ELISA.
Immunofluorescence microscopy. Paraffin-embedded human left ventricular (LV) myocardial tissues were obtained at autopsy from an individual not affected with any cardiac diseases. Informed consent was given from relatives of the subject. Heart samples from hHS-M 21 Tg mice were prepared as previously described (1) . Deparaffinized tissue sections were incubated for 10 min with antigen liberation solution [0.01 M citrate buffer (pH 6.0)] at 120°C and incubated with blocking solution (10% bovine serum and 0.03% Triton X-100 in PBS) for 1 h at room temperature. Sections were then incubated with primary rabbit-polyclonal antibody against hHS-M 21 or His6-tag (Santa Cruz Biotechnology) diluted in incubation buffer (3% bovine serum and 0.03% Triton X-100 in PBS) overnight at 4°C. Sections were washed three times with 0.03% Triton X-100 in PBS and incubated with Alexa fluor 568 goat anti-rabbit IgG (Molecular Probes) for 1 h at room temperature. Immunoreaction against telethonin protein was then performed on the sections using the Vector M.O.M. Immunodetection Kit (Vector Laboratories) according to the manufacturer's instructions. The antibodies used were primary mouse anti-telethonin monoclonal (BD Biosciences) and secondary Alexa fluor 488 rabbit anti-mouse IgG (Molecular Probes). All tissue sections were mounted on coverglasses using Mowiol 4-88 Reagent (Calbiochem), and images were analyzed with a LSM510 laser scanning microscope (Carl Zeiss Microscopy).
Preparation of skinned fibers and force measurements. Ventricles dissected from hearts of mice at 2 mo of age were skinned with 0.5% Brij-58; a small fiber (~200 m in diameter) was dissected from LV papillary muscle, and isometric force was measured as previously described (15) .
Echocardiography, ECG, and blood pressure measurement. Transthoracic echocardiography, ECG analysis, and heart rate (HR) were performed as previously described (2, 14) . Transthoracic echocardiography was performed using a model Prosound SSD-5000 (Aloka) with a 10-MHz transducer under slight anesthesia with 1% isoflurane in O 2. LV parameters were obtained from two-dimensional and M-mode and calculated from the mean of at least three separate cardiac cycles. ECG with standard limb leads was recorded under pentobarbital anesthesia (intraperitoneal injection, 30 mg/kg body wt). A heat pad was used during the recording to prevent hypothermia. ECG analysis was performed using an ECG processor (Softron). HR was measured in the conscious state with a tail-cuff blood pressure analyzer (MK-2000, Muromachi) .
Histopathological examinations. Mice were euthanized by a lethal dose of pentobarbital sodium (intraperitoneal injection, 150 mg/kg), and freshly removed hearts were fixed in 10% phosphate-buffered formalin, embedded in paraffin wax, sectioned at 5 m, and stained with hematoxylin and eosin or Masson's trichrome by standard methods. Representative stained sections were photographed using a BX50-33SP light microscope attached to a DP25 digital camera (Olympus). Images were processed using Adobe Photoshop 7.0 (Adobe Systems). Measurements of interstitial fibrosis area and quantitative analysis of collagen in the heart were performed as previously described (2) . Interstitial fibrosis was stained with picrosirius red using Sirius red F3B (Sigma-Aldrich) to color collagen on cardiac sections, and interstitial collagen density was quantified using ImageJ software. Quantitative analysis of collagen in the heart was also performed using a Semi-Quantitative Collagen Assay Kit (Chondrex) according to the manufacturer's instructions. Electron microscopy. Sample preparations of cardiac muscle were performed as previously described (9) . Briefly, control and hHS-M21 Tg32 mice at 5 mo of age were euthanized and perfusion fixed through the LV with 2% paraformaldehyde and 2% glutaraldehyde in 0.15 M sodium cacodylate buffer. Small blocks of the LV free wall were postfixed for 2 h with the same fixative solution. The fixed tissues were incubated in 0.8% potassium ferrocyanide and 2% osmium tetroxide in 0.15 M sodium cacodylate buffer, and the tissue blocks were stained with 1% uranyl acetate. The tissue blocks were then dehydrated in a graded series of ethanol and embedded in Durcupan ACM (Sigma). Images of thin sections (70 nm) from the embedded block were taken with a H-7100 (Hitachi) electron microscope at 80 keV.
Administration of fasudil. Long-term oral administration of the ROCK inhibitor agent fasudil (100 mg·kg Ϫ1 ·day Ϫ1 in the drinking water) was performed in hHS-M 21 Tg32 mice. The administration was started at 2 mo of age, just after the first echocardiographic study, and continued until 8 mo of age.
Protein extraction and immunoblot analysis. LVs were excised from mice and homogenized in total protein extraction buffer (2% SDS, 250 mM sucrose, 75 mM urea, 1 mM dithiothreitol, and 50 mM Tris·HCl, pH 7.5) containing phosphatase inhibitors (10 mM NaF and 2 mM Na3VO4) and a protease inhibitor cocktail (Sigma-Aldrich). After the measurement of protein concentration using the BCA protein assay kit (Pierce), equal amounts of proteins were subjected to SDS-PAGE, transferred to nitrocellulose membranes (Invitrogen), and blotted with the following primary rabbit-polyclonal antibodies: 1) anti-hHS-M21 antibody (against for hHS-M21 and MYPT2); 2) anti-MYPT1, anti-His 6- 19 ) antibody (Cell Signaling Technology). For the quantification of ventricular/cardiac muscle MLC2 (MLC2v) phosphorylation, LVs were homogenized in a urea sample buffer [8 M urea, 300 mM sucrose, 10 mM dithiothreitol, 50 mM Tris·HCl (pH 6.8) and 0.01% bromophenol blue] containing phosphatase inhibitors and a protease inhibitor cocktail. Extracts were subjected to glycerol-urea PAGE (13, 17) after immunoblot analysis using primary mouse monoclonal anti-MLC2v antibody (BioCytex) or rabbit polyclonal anti-MLC2v antibody (kindly provided from Dr. Seiji Takashima, Osaka University Graduate School of Medicine). Membranes were incubated with secondary rabbit anti-mouse or goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated antibody (Dako A/S). Signals were visualized by Immobilon Western Chemiluminescent HRP Substrate (Millipore) and Luminescent Image Analyzer LAS-3000mini (Fujifilm). Signal densities were quantified by using MultiGauge ver3.0 (Fujifilm), and the signal generated using antibody against GAPDH was used as an internal control to normalize protein amounts on the immunoblots.
Microarray processing. Microarray analysis was performed using Mouse Genome 430 2.0 GeneChip Arrays (Affymetrix). cDNA synthesis, cRNA synthesis, and labeling were performed as previously described (16) . Hybridization, washing, staining, and scanning of arrays were performed at the Gene Chip Core Facility of the Columbia University Genome Center (16) .
Microarray data analysis. Image files were obtained through Affymetrix GeneChip software and analyzed by MAS5. Raw data were normalized and analyzed in GeneSpring software version X.7.3.1 (Silicon Genetics). It was called "present" in 29,204 of 45,101 probe sets based on values of 1.5 to 140 determined by a filter on the expression level. Patterns of gene expression were identified using a principal component analysis and a hierarchical clustering algorithm to indicate related expression. Genes were identified as differentially expressed if they met a false discovery rate threshold of 0.05 in a two-sample t-test (q-value) and showed at least a twofold difference in expression independent of absolute signal intensity. Differences in expression level using statistical analysis (ANOVA) were then calculated for all present individual genes in hearts from hHS-M21 Tg6 and Tg32 mice based on a comparison with control mice. Quantitative real-time RT-PCR analysis was performed as previously described (16) .
Statistical analysis. All physiological and pathological data were acquired and analyzed by observers who were blinded to the genotype of mice. Numeric data are expressed as means Ϯ SE. Statistical differences were analyzed using one-way ANOVA and then evaluated using a Tukey-Kramer adjustment for post hoc test. Survival curves were drawn for each group with the Kaplan-Meier method, and the differences were compared by a log-rank test. P Ͻ 0.05 was considered statistically significant.
RESULTS

Generation of hHS-M 21 Tg mice.
To investigate the function of hHS-M 21 in the development of cardiomyopathy, we overexpressed hHS-M 21 cDNA under the control of the mouse ␣-MHC promoter (Fig. 1A) . Tg mice were generated on a C57BL/6J background, and the progeny were screened for germline transmission of the transgene. All founders were fertile and produced progeny. Of the six founders, three founders (lines 22, 25, and 27) displayed no cardiac expression of the hHS-M 21 transgene, two founders (lines 29 and 32 for Tg29 and Tg32, respectively) strongly expressed the hHS-M 21 transgene, and one founder (line 6 for Tg6) showed weak expression of the hHS-M 21 transgene (Fig. 1B) . Immunoblot analysis of hHS-M 21 expression in various tissues indicated that hHS-M 21 transgene expression was restricted to heart (ventricle and atrium) and not detectable in other tissues analyzed (Fig. 1C) . hHS-M 21 was localized at the Z-disk of sarcomeres (Fig. 1D ), similarly to endogenous staining in the human heart (Fig. 1D) . Tg mice were born in the expected Mendelian ratio and were indistinguishable from their non-Tg control littermate. Both Tg32 and Tg29 mice (male and female), but not Tg6 mice, had a shortened life expectancy compared with control mice (Fig.  1E ). All Tg32 mice died between 10 and 12 mo, whereas all Tg29 mice died by 20 mo of age (Fig. 1E) . No significant sex difference in survival was observed in both Tg32 and Tg29 mice.
Overexpression of hHS-M 21 impairs LV function. We next examined whether overexpression of hHS-M 21 leads to structural abnormalities and causes cardiac muscle pathology. Both Tg29 and Tg32 mice developed progressive LV dilation and contractile dysfunction, as evidenced by decreased LV fractional shortening and decreased LV ejection fraction ( Fig. 2A and Table 1 ). LV dysfunction was observed at 2 mo of age for Tg32 mice and at 4 mo of age for Tg29 mice ( Table 1 ). The electrical consequences of hHS-M 21 overexpression in mice were studied by surface ECG. The PR interval was prolonged in 2-mo-old Tg29 and Tg32 mice compared with control mice, and the QRS complex duration was significantly prolonged only in 2-mo-old Tg32 mice ( Fig. 2B and Table 2 ). In addition, statistically significant decreased HR and prolonged PR intervals were found in both Tg32 and Tg29 mice after 2 mo of age (Table 2 ). These observations indicated that hHS-M 21 Tg mice develop sinus bradycardia and atrioventricular conduction disturbance.
Histological analysis of hearts from Tg29 and Tg32 mice at the age of 6 mo revealed dilated ventricles accompanied by enlargement of the atrial cavity (Fig. 2C) and evidence of interstitial fibrosis (Fig. 2, C and D) . We also observed myofibrillar disarray and Z-disk abnormalities in hearts from Tg32 mice (Fig. 2E) .
Overexpression of hHS-M 21 increases Ca
2ϩ sensitivity in vivo. The effect of hHS-M 21 overexpression on cardiac Ca 2ϩ sensitivity was studied using skinned cardiac muscle fibers prepared from Tg29 and Tg32 mice at 2 mo of age. Cardiac muscle fibers from Tg mice showed significant differences in the Ca 2ϩ sensitivity of force generation compared with control mice but not in the maximum force-generating capability (Fig.  3A) . These results demonstrated that hHS-M 21 exerted the Ca 2ϩ sensitization of cardiac muscle in vivo. Given that phosphorylation of MLC is involved in the regulation of Ca 2ϩ sensitivity, we next studied the expression and phosphorylation status of key actors of MLC activation (Fig. 3B) . We observed no significant difference in the expression of MYPT2 and PP1c␦ in hearts from Tg29 and Tg32 mice at 2 mo of age compared with control mice, although we found a significant increase of MYPT1 isoforms (18) in Tg29 and Tg32 hearts, a significant increase of ROCK2 in Tg32 hearts, and a significant decrease of RhoA, an activator of ROCK, in Tg29 and Tg32 hearts (Fig. 3, C and D) . Furthermore, the phosphorylated MYPT1 level was not changed between Tg29 and Tg32 mice compared with control mice (Fig. 3, C and D) . To our surprise, significantly decreased phosphorylation of the two major cardiac MLC isoforms, smMLC2 and MLC2v, was observed in hearts from both Tg29 and Tg32 mice at 2 mo of age compared with control mice (Fig. 3, E and F) . The phosphorylation status of cardiac MLC2 isoforms was also decreased in Tg mice at 4 mo of age (data not shown). These data suggested that the increased Ca 2ϩ sensitivity observed in Tg mice was not mediated by phosphorylation of smMLC2 or MLC2v.
Fasudil treatment improves cardiac function in hHS-M 21 Tg animals. Given that ROCK signaling phosphorylates MYPT and inhibits MLCP activity, we hypothesized that decreasing the activity of this pathway would prevent the progression of LV dysfunction and conduction defects. We treated control and Tg32 mice with fasudil, a potent ROCK inhibitor, for 6 mo. Fasudil significantly improved LV fractional shortening and LV ejection fraction in Tg32 mice at 4, 6, and 8 mo of age compared with age-matched placebo-treated mice (Table 3 ). In addition, fasudil treatment decreased the level of interstitial fibrosis compared with placebo (data not shown). However, 
Values are means Ϯ SE. Cardiac function was evaluated by transthoracic echocardiographic analyses of the left ventricle (LV). LV mass (LVM) and LV fractional shortening (LVFS) were calculated as follows: [(IVSd ϩ PWd ϩ EDD)
3 Ϫ EDD 3 ] ϫ 1.055 and (LVEDD Ϫ LVESD)/LVEDD ϫ 100, respectively, where IVSd is the interventricular septal wall thickness at diastole, PWd is the posterior wall thickness at diastole, EDD is end-diastolic diameter, LVEDD is LV end-diastolic diameter. LVESD is LV end-systolic diameter, and LVEF is LV ejection fraction. hHS-M21 Tg mice, heart-specific myosin light chain phosphatase small subunit transgenic mice; WT mice, wild-type mice. *P Ͻ 0.05, †P Ͻ 0.01, and ‡P Ͻ 0.001 vs. age-and sex-matched WT mice.
HR, P duration, and PR interval were not improved by treatment with fasudil (Table 4) .
Overexpression of hHS-M 21 alters cardiac gene expression.
To identify abnormal gene expression associated with the development of cardiomyopathy in hHS-M 21 Tg mice, we carried out a genome-wide RNA expression analysis in hearts from Tg32 mice. We also analyzed hearts from Tg6 mice, which showed weak expression of hHS-M 21 without any cardiac phenotypes. To focus on the primary events and avoid any interferences caused by fibrotic cells and nonspecific tissue damage in aged mice, we analyzed heart samples from mice at 10 wk of age. Intragroup scatterplots of log-transformed expression values showed a good correlation between the different samples (Fig. 4A) . To compare the global gene expression profiles in hearts from different groups of mice, we performed a principal component analysis, and a clear separation of Tg lines from control was observed (Fig. 4B) . Hierarchical cluster analysis revealed a strong consistency between replicates and distinct patterns of gene expression in Tg mice (Fig. 4C) . Compared with control mice, both Tg6 and Tg32 mice exhibited a large cluster of genes with increased expression and a small cluster of genes with decreased expression. We then used a supervised learning method to distinguish genes with significant differences in expression among Tg6 and Tg32 mice. The analysis identified 3,757 and 3,122 probe sets showing differential cardiac expression pattern in Tg6 and Tg32 mice, respectively ( Fig. 4D and Supplemental Tables S1 and S2 in the Supplemental Material; Supplemental Material for this article is available at the American Journal of Physiology-Heart and Circulatory Physiology website). Although the gene expression profiles of both Tg6 and Tg32 mice showed a pattern indicative of molecular signature in cardiomyopathy (upregulation of cardiac remodeling-related genes including Myh7, Myl7, Myl4, and Mylc2b), Tg32 mice showed an upregulation of genes representative of cardiac hypertrophy and/or cardiac failure such as atrial natriuretic peptide and brain natriuretic peptide. To validate the altered expression of selected transcripts (Myh7, Myl7, and Myl4) identified from the microarray analysis, we performed real-time RT-PCR using RNA extracted from mouse hearts. There was a good correlation between real-time RT-PCR and microarray data (Supplemental Table S3 ). We also analyzed Gene Ontology terms to identify functional classes of genes differentially expressed in Tg6 and Tg32 hearts compared with control hearts. In Tg6 and Tg32 hearts, the high-scoring Gene Ontology classes showed groups of genes encoding proteins involved in inflammation and muscle cell development (Supplemental Tables S4 and S5 ). In contrast, abnormal expression of genes associated with MAPK signaling and transforming growth factor-␤ signaling pathways was observed only in Tg32 mice (Supplemental Table S5 ). We next investigated which genes were uniquely detected in each Tg line. Comparison of the genes detected in each sort by Venn diagram revealed similarities between Tg6 and Tg32 mice ( Fig. 4D and Supplemental Table S6 ).
DISCUSSION
To better define the role of hHS-M 21 in cardiac physiology, we overexpressed hHS-M 21 in the heart and studied how it affects cardiac function. We showed that mice with cardiacspecific overexpression of hHS-M 21 progressively developed Table 2 . ECG characteristics of WT and hHS-M 21 Values are means Ϯ SE. hHS-M21 Tg mice, heart-specific myosin light chain phosphatase small subunit transgenic mice; WT mice, wild-type mice. *P cardiomyopathy, resulting in a poor survival prognosis. hHS-M 21 Tg mice showed sinus bradycardia and conduction disturbance. Given that we previously reported that hHS-M 21 was a heart-specific effector of ROCK (21), we suggested that the activation of ROCK signaling by hHS-M 21 played a deleterious role in the progression of HF. ROCK phosphorylates MYPT1 (Thr
Tg mice
696
) and inhibits MLCP activity (8, 10) . The decreased catalytic activity of MLCP induces MLC2 phosphorylation, resulting in Ca 2ϩ sensitization of contractility (8, 10) . Therefore, we thought that hHS-M 21 would modulate MYPT1 phosphorylation and increase Ca 2ϩ sensitivity of cardiac muscle contraction via activation of ROCK. As a result, the Ca 2ϩ sensitivity of muscle contraction was increased in hHS-M 21 Tg mice. The increased Ca 2ϩ sensitivity was very small. However, it should be noted that the force-pCa relationship in cardiac muscle is very steep so that even a very small increase in myofilament Ca 2ϩ sensitivity would cause a physiologically significant increase in myocardial force generation. However, we demonstrated that overexpression of hHS-M 21 decreased the phosphorylation of cardiac MLC2, although ROCK expression and MYPT1 phosphorylation were increased. This apparent discrepancy is enigmatic, and our result implies that there may be other target molecule(s) in the downstream of hHS-M 21 activation. Overall, it was suggested that hHS-M 21 might also be involved in the non-MLC2-phosphorylation-dependent regulation of cardiac performance, such as direct regulation of intracellular Ca 2ϩ or structural/functional alterations in Ca 2ϩ regulatory protein or in non-Ca 2ϩ -dependent regulation, such as altered reactivity of cytoskeletal actin with myosin cross bridges. In addition, the phosphorylation of MYPT1 at Thr (MYPT1-pThr 696 and MYPT1-pThr 853 ) were normalized to the amounts of total MYPT1. Data were represented as intensities, and that in a LV from a WT mouse was arbitrarily defined as 1.00 arbitrary unit (AU). Data are expressed as means Ϯ SE for n ϭ 4Ϫ6 mice/group. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001. E: representative immunoblots for smooth muscle MLC2 (smMLC2) and phospho-smMLC-Ser 19 (pSer 19 ) in total protein extracts from LVs of WT and hHS-M21 Tg (Tg29 and Tg32) mice at 2 mo of age are shown (top). Representative immunoblots for nonphosphorylated (nonP), monophosphorylated (P1), and diphosphorylated (P2) ventricular/cardiac muscle MLC2 (MLC2v) using mouse monoclonal (mono Ab) and rabbit polyclonal (poly Ab) anti-MLC2v antibodies are shown. Phosphorylation levels of MLC2v were determined by glycerol-urea PAGE (bottom). Vertical dividing lines were inserted to identify noncontiguous lanes. F: densitometric analysis of blot data for smMLC2-Ser 19 phosphorylation (pSer 19 ). The smMLC2-pSer 19 level was normalized to the amount of total smMLC2. Data are represented as intensities, and that in a LV from a WT mouse was arbitrarily defined as 1.00 AU. Densitometric data showing the relative amounts of phosphorylated (P1 ϩ P2) MLC2v to total (nonP ϩ P1 ϩ P2) MLC2v are also shown. Data are expressed as means Ϯ SE for n ϭ 4Ϫ6 mice/group. ***P Ͻ 0.001. creased, MYPT1 expression was also increased, which suggested transcriptional regulation, resulting in the ratio of pThr 696 -MYPT1 to MYPT1 being unchanged. Further studies are required to fully unveil the molecular mechanisms and consequence of the hHS-M 21 activation, not only focused on the MLC2-phosphorylation-dependent pathway.
The analysis of global gene expression in the early stage of cardiomyopathy in mice overexpressing hHS-M 21 revealed an upregulation of genes associated with cardiac remodeling. In addition, by focusing on molecular pathways and gene ontology classification, the contribution of genes related to transforming growth factor-␤ and its receptor signaling pathways were identified, consistent with the development of HF with cardiac fibrosis and degeneration. We also revealed an altered expression of genes involved in activation of the MAPK signaling pathway. Results from previous studies have implicated activation of the MAPK cascade in the development of HF in both humans and mice (16, 23) . Interestingly, Wang et al. (24) demonstrated that the ROCK inhibitor fasudil improved isoproterenol-induced HF in rats associated with inhibition of MAPK signaling. These observations raise the possibility that hHS-M 21 may play a role in activation of the MAPK signaling pathway in the heart as a heart-specific effector of ROCK. This needs further investigation.
We evaluated the effect of the ROCK inhibitor fasudil as a potential therapeutic agent on the cardiac manifestations in Tg mice. Fasudil administration clearly restored the cardiac contractility and improved the prognosis, in line with a previous report that long-term treatment with fasudil prohibited the progression of pathological cardiac remodeling, fibrosis, and hypertrophy in mice and rats (28 -31). However, in clear contrast to the effects on HF, fasudil could not improve HR and PR duration in hHS-M 21 Tg mice. Supraventricular arrhythmias including sinus bradycardia and atrioventricular block are often associated with progressing HF, which, in turn, indicates that prophylactic therapeutics for HF would decrease the risks for supraventricular arrhythmias. It is suggested in this study that supraventricular electrical properties are more or less dependent on hHS-M 21 but independent from HF progression, at least in this animal model, implying that the supraventricular arrhythmia may not always be a consequence of HF in humans. In addition, because of the methodological limitation, we were not able to analyze the transition of plasma concentration, medicinal effect, and metabolism of fasudil from the beginning to end of the administration period in the treated mice. These might be important to evaluate the results in this study of the continuous multiple administration test on the metabolism and effect of fasudil during such a long-term oral administration in mice.
In conclusion, we created hHS-M 21 Tg mice that showed increased Ca 2ϩ sensitivity of cardiac muscle contraction. hHS-M 21 Tg mice developed HF with poor survival prognosis, which was improved by treatment with the ROCK inhibitor fasudil. An intriguing finding was that the phosphorylation levels of MYPT1 and MLC2 isoforms were not increased in hHS-M 21 Tg hearts. In addition, although we have not completely solved the molecular basis underlying the pathology, it was suggested that MAPK and transforming growth factor-␤ signaling pathways were involved in the pathogenesis of cardiac abnormalities in hHS-M 21 Tg mice. Our findings imply that hHS-M 21 Tg mice represent a good model for studying the pathogenesis of cardiomyopathy associated with conduction disturbance.
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